Skip to content

Journal · Dermatology · Updated 15 November 2026

JAMA Dermatology

Read JAMA Dermatology research on DeepDyve. No university library needed.

JAMA Dermatology is a dermatology journal published by the American Medical Association, under its current title since 2013. Its papers cover the diagnosis and treatment of skin conditions, from melanoma and squamous cell carcinoma to vitiligo, along with consensus guidelines and clinical cases. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including the American Medical Association.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

JAMA Dermatology at a glance

Full title
JAMA Dermatology
Abbreviation (NLM)
JAMA Dermatol
Publisher
American Medical Association
Print ISSN
2168-6068
Online ISSN (eISSN)
2168-6084
Current title since
2013
Subjects
Dermatology
Access model
Subscription
On DeepDyve
Research articles; availability varies by article

Ways to access JAMA Dermatology

JAMA Dermatology is a subscription journal. To read its articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. The authors’ accepted manuscript. JAMA Network lets authors post the accepted manuscript of original research in a repository of their choice on the day of publication. Search the title in PubMed Central, Google Scholar or the authors’ university repository.
  2. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  3. A library. Your university, hospital or public library may subscribe to JAMA Dermatology. Check its journal list and whether it offers remote access.
  4. DeepDyve. Read JAMA Dermatology articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: AMA on JAMA Network’s manuscript policy; NIH Public Access Policy.

Recent JAMA Dermatology research worth reading

Published May to August 2026. Summaries describe what the authors report.

  1. LitStreamDermatology · Skin cancer imaging

    Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma

    In a Delphi consensus of 45 experts, the authors report agreement on staging and surveillance imaging for cutaneous squamous cell carcinomas with at least a 15% risk of metastasis, with CT the preferred modality for nodal staging and surveillance imaging recommended for at least 2 years.

    JAMA Dermatology, July 2026 · DOI 10.1001/jamadermatol.2026.2163

  2. LitStreamDermatology · Squamous cell carcinoma

    Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

    In a prospective case series of 15 patients with advanced cutaneous squamous cell carcinoma of the head and neck given capecitabine before surgery, the authors report that 10 (67%) had clinical tumor regression, with no grade 3 or higher capecitabine-related toxic effects.

    Haidar et al. · JAMA Dermatology, published online August 1, 2026 · DOI 10.1001/jamadermatol.2026.1331

  3. Open accessDermatology · Vitiligo

    Clinical Characteristics and Treatment Patterns in Patients With Vitiligo

    In a retrospective cohort study of 24,949 US patients with vitiligo, the authors found that the face was the most frequently affected area, about one-third of patients received no vitiligo treatment after diagnosis, and topical corticosteroids were among the most common treatments.

    Adiri et al. · JAMA Dermatology, published online July 1, 2026 · DOI 10.1001/jamadermatol.2026.0971

  4. LitStreamDermatology · Familial melanoma

    Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals

    Studying 696,665 people from population-scale genomic cohorts in the UK and US, the authors report that pathogenic variants in familial melanoma genes had a combined prevalence of 0.5% to 0.9%, exceeding the 2.5% clinical testing threshold in people with multiple melanomas or a first melanoma before age 40.

    JAMA Dermatology, May 2026 · DOI 10.1001/jamadermatol.2026.1305

See every JAMA Dermatology article on DeepDyve

Questions about JAMA Dermatology

How can I read JAMA Dermatology articles without a subscription?

JAMA Network lets authors post the accepted manuscript of original research in a repository of their choice on the day of publication. Search the title in PubMed Central, Google Scholar or the authors’ university repository. Your library may also subscribe. DeepDyve lets you read JAMA Dermatology articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for JAMA Dermatology?

JAMA Dermatology’s NLM (PubMed) abbreviation is JAMA Dermatol.

What is the ISSN of JAMA Dermatology?

The print ISSN is 2168-6068 and the online ISSN is 2168-6084.

Is JAMA Dermatology open access?

JAMA Dermatology articles are published under the subscription model; none of the 313 articles it published from January 1 to November 14, 2026 carry a Creative Commons license in Crossref.

JAMA Dermatology articles on DeepDyve are licensed from the American Medical Association. Journal facts as of 15 November 2026.

Start reading JAMA Dermatology today

One month free, then less than $2 a day. JAMA Dermatology, plus millions of articles from thousands of journals.

Start free month

Like this: